DEDICATED TO THE CURE OF DENSE DEPOSIT DISEASE

 

For patients and families

For physicians

Research

Benefits

FAQ

 

FDA approves limited trial to study CDX-1135

FDA approves limited trial to study CDX-1135

"FDA evaluation of this drug (CDX-1135) is a major milestone for me and for all DDD patients. It is paving a path to new possibilities and options for treating this dreadful disease. I thank everyone who has been there with us, all who are celebrating this news, and those who are as excited to see where we are going as I am! Thank you to everyone who has helped make this day happen for me and for all of us with DDD!” – Jenna Smith

 

 

 

 

 

 

CDX-1135 is a drug that is under evaluation as the first disease-specific therapy for DDD. For information on this FDA-approved study visit ClinicalTrials.gov.